FDA Stresses Need For Routine Monitoring Of Endovascular Aortic Repair Patients
Executive Summary
A new letter to providers says that to ensure potential adverse events can be identified early, patients should be checked via imaging at 30 days after surgery and at least once a year thereafter.
You may also be interested in...
Find Alternatives To Endologix AFX For Treating Abdominal Aortic Aneurysms, FDA Advises
In its most recent update on the use of Endoglox AFX endovascular grafts, the US FDA is advising physicians use other devices for treating patients with abdominal aortic aneurysms (AAA). AFX still poses bleeding risk.
Bleeding Risks Still A Concern For Patients With Endologix Stent Grafts: FDA Advisory Panel
The US agency’s Circulatory System Devices Panel found type III endoleaks are still a problem for abdominal aortic aneurysm patients treated with the newest Endologix stent graft, though for some the benefits still outweigh the risks. The panel advised that all patients, however, should continue getting annual screenings.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.